AU2010306671B2 - Compositions and methods for the treatment of drug-induced hand-foot syndrome - Google Patents

Compositions and methods for the treatment of drug-induced hand-foot syndrome Download PDF

Info

Publication number
AU2010306671B2
AU2010306671B2 AU2010306671A AU2010306671A AU2010306671B2 AU 2010306671 B2 AU2010306671 B2 AU 2010306671B2 AU 2010306671 A AU2010306671 A AU 2010306671A AU 2010306671 A AU2010306671 A AU 2010306671A AU 2010306671 B2 AU2010306671 B2 AU 2010306671B2
Authority
AU
Australia
Prior art keywords
drug
ppe
subject
phosphodiesterase inhibitor
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010306671A
Other languages
English (en)
Other versions
AU2010306671A1 (en
Inventor
Herbert Hurwitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of AU2010306671A1 publication Critical patent/AU2010306671A1/en
Application granted granted Critical
Publication of AU2010306671B2 publication Critical patent/AU2010306671B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010306671A 2009-10-16 2010-10-15 Compositions and methods for the treatment of drug-induced hand-foot syndrome Ceased AU2010306671B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27909109P 2009-10-16 2009-10-16
US61/279,091 2009-10-16
PCT/US2010/052836 WO2011047256A1 (en) 2009-10-16 2010-10-15 Compositions and methods for the treatment of drug-induced hand-foot syndrome

Publications (2)

Publication Number Publication Date
AU2010306671A1 AU2010306671A1 (en) 2012-05-10
AU2010306671B2 true AU2010306671B2 (en) 2015-12-17

Family

ID=43876575

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010306671A Ceased AU2010306671B2 (en) 2009-10-16 2010-10-15 Compositions and methods for the treatment of drug-induced hand-foot syndrome

Country Status (6)

Country Link
US (2) US9220713B2 (https=)
EP (1) EP2488642B1 (https=)
JP (2) JP2013508295A (https=)
CN (1) CN102648279B (https=)
AU (1) AU2010306671B2 (https=)
WO (1) WO2011047256A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2488642B1 (en) * 2009-10-16 2015-03-11 Duke University Compositions and methods for the treatment of drug-induced hand-foot syndrome
US20140127295A1 (en) * 2011-03-14 2014-05-08 Cellworks Group, Inc Compositions, process of preparation of said compositions and method of treating inflammatory diseases
CA2914815A1 (en) * 2013-06-11 2014-12-18 Kala Pharmaceuticals, Inc. Urea derivatives and uses thereof
WO2016144230A1 (en) * 2015-03-06 2016-09-15 Telefonaktiebolaget Lm Ericsson (Publ) Method, network device, computer program and computer program product for mobile service chaining
EP3444337B1 (en) * 2017-08-18 2024-12-18 The Procter & Gamble Company Method of cleaning
WO2019114705A1 (zh) 2017-12-13 2019-06-20 上海小午医药科技有限公司 一种用于预防或治疗与egfr被抑制相关疾病的方法
CN111989095A (zh) 2018-04-16 2020-11-24 上海岸阔医药科技有限公司 预防或治疗肿瘤疗法副作用的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9004A (en) * 1852-06-08 Improvement in seed-planters
US2002A (en) * 1841-03-12 Tor and planter for plowing
US9019A (en) * 1852-06-15 Charles fleischbl
US20020028237A1 (en) 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
MXPA03006936A (es) * 2001-02-02 2003-11-18 Pfizer Tratamiento de diabetes mellitus.
WO2006091542A2 (en) * 2005-02-22 2006-08-31 Cedars-Sinai Medical Center Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier
US20090048179A1 (en) * 2005-02-22 2009-02-19 Cedars-Sinai Medical Center Use of 5-phosphodiesterase inhibitors to enhance the permeability of the blood-brain barrier of abnormal brain tissue and the blood-tumor barrier
WO2007056457A2 (en) 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
WO2007087575A2 (en) * 2006-01-24 2007-08-02 University Of Chicago Compositions and methods for treating pulmonary hypertension
US7973046B2 (en) 2006-06-01 2011-07-05 Nobera Pharma, S.L. Use of allopurinol for the treatment of palmar plantar erythrodysesthesia
EP2246057A1 (en) 2009-04-29 2010-11-03 Nobera Pharma, S.L. Use of allopurinol for the treatment of hand foot skin reaction
EP2488642B1 (en) * 2009-10-16 2015-03-11 Duke University Compositions and methods for the treatment of drug-induced hand-foot syndrome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PUSZTAI, L., et al., Journal of Clinical Oncology, 2003, vol. 21, pages 3454-3461 *

Also Published As

Publication number Publication date
EP2488642A4 (en) 2013-03-06
AU2010306671A1 (en) 2012-05-10
CN102648279A (zh) 2012-08-22
JP2013508295A (ja) 2013-03-07
US20120258970A1 (en) 2012-10-11
EP2488642A1 (en) 2012-08-22
EP2488642B1 (en) 2015-03-11
WO2011047256A1 (en) 2011-04-21
JP6063550B2 (ja) 2017-01-18
US9220713B2 (en) 2015-12-29
US9629845B2 (en) 2017-04-25
US20160074405A1 (en) 2016-03-17
JP2016094450A (ja) 2016-05-26
CN102648279B (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
US9629845B2 (en) Compositions and methods for the treatment of drug-induced hand-foot syndrome
ES3036485T3 (en) Combination comprising everolimus and amcenestrant
JP2020055884A (ja) がんのためのグルフォスファミド組み合わせ療法
EP4322941A1 (en) Combination comprising ribociclib and amcenestrant
CN108025007A (zh) 曲美他嗪在制备防治肝病的药物中的用途
US20170027977A1 (en) Methods useful in the prevention of hypoxic injury
Othman et al. Combined Ketamine and Midazolam Versus Midazolam Alone for Initial Treatment of Pediatric Generalized Convulsive Status Epilepticus (Ket-Mid Study): A Randomized Controlled Trial
WO2021023291A1 (zh) 原黄素在肺癌治疗中的应用
CN120919330A (zh) 预防和/或治疗哺乳动物心脏系统疾病的药物组合物
KR20200050761A (ko) 다이설피람을 포함하는 항암용 조성물
CN103599111B (zh) 用于治疗胰腺癌的组合药物
Biesma et al. A dose and schedule finding study of gemcitabine and etoposide in patients with progressive non-small cell lung cancer after platinum containing chemotherapy
WO2023026247A1 (en) Combination of a nurr1 agonist with at least one of an aldosterone antagonist, an insulin modulator and a sulfonylurea
KR20240005881A (ko) 빈혈 치료를 위한 펠라브레시브의 용도
EP4181887A1 (en) Pde3 inhibitors for treating viral infections
CN110876803B (zh) 一种包含乳蛋白和油酸的药物组合物
IT202300010005A1 (it) Rutina per il trattamento dell’epidermolisi bollosa
CN121285550A (zh) 一种吡咯并[2,3-c]吡啶酮化合物的联用药物组合物及其用途
EP4452275A1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers
CN119302935A (zh) 苄索氯胺作为stat3抑制剂在制备治疗头颈部肿瘤药物的应用
CN119907669A (zh) 用于治疗肝损伤的硝唑尼特
KR20130020945A (ko) 골수이형성 증후군을 치료하기 위한 조성물 및 방법
JP2008501785A (ja) 子宮腫瘍の治療用医薬の調製のための７−ｔ−ブトキシイミノメチルカンプトテシンの使用
KR20190046937A (ko) 만성 골수성 백혈병을 치료 또는 관해하기 위한 의약 조성물
Senanayake et al. Profound thrombocytopenia and generalized hyperpigmentation following pyrimethamine use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)